vs
IT TECH PACKAGING, INC.（ITP）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是IT TECH PACKAGING, INC.的1.2倍（$30.3M vs $25.6M），IT TECH PACKAGING, INC.净利率更高（-5.7% vs -221.3%，领先215.7%），REGENXBIO Inc.同比增速更快（43.0% vs 2.1%），IT TECH PACKAGING, INC.自由现金流更多（$1.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 10.5%）
IT TECH PACKAGING, INC.是一家主营纸制品研发生产的企业，核心市场布局在中国境内，核心产品包括瓦楞包装纸、箱板纸、印刷用文化纸等，下游覆盖消费品包装、物流运输、商业印刷等多个需求领域。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ITP vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.2倍
$25.6M
营收增速更快
RGNX
高出40.9%
2.1%
净利率更高
ITP
高出215.7%
-221.3%
自由现金流更多
ITP
多$54.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
10.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $25.6M | $30.3M |
| 净利润 | $-1.4M | $-67.1M |
| 毛利率 | 7.9% | — |
| 营业利润率 | -3.9% | -190.0% |
| 净利率 | -5.7% | -221.3% |
| 营收同比 | 2.1% | 43.0% |
| 净利润同比 | 26.6% | -31.2% |
| 每股收益（稀释后） | $-0.11 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ITPRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $25.6M | $29.7M | ||
| Q2 25 | $24.8M | $21.4M | ||
| Q1 25 | $10.9M | $89.0M | ||
| Q4 24 | $17.6M | $21.2M | ||
| Q3 24 | $25.1M | $24.2M | ||
| Q2 24 | $26.2M | $22.3M | ||
| Q1 24 | $6.9M | $15.6M |
净利润ITPRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $-1.4M | $-61.9M | ||
| Q2 25 | $-2.0M | $-70.9M | ||
| Q1 25 | $-3.5M | $6.1M | ||
| Q4 24 | $-4.0M | $-51.2M | ||
| Q3 24 | $-2.0M | $-59.6M | ||
| Q2 24 | $-77.7K | $-53.0M | ||
| Q1 24 | $-3.7M | $-63.3M |
毛利率ITPRGNX
| Q4 25 | — | — | ||
| Q3 25 | 7.9% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 0.8% | — | ||
| Q4 24 | 6.3% | 70.2% | ||
| Q3 24 | 7.6% | 48.8% | ||
| Q2 24 | 12.4% | 52.5% | ||
| Q1 24 | 5.8% | 72.6% |
营业利润率ITPRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | -3.9% | -176.3% | ||
| Q2 25 | -7.1% | -296.3% | ||
| Q1 25 | -31.0% | 13.6% | ||
| Q4 24 | -21.5% | -242.1% | ||
| Q3 24 | -5.8% | -256.6% | ||
| Q2 24 | 2.1% | -251.3% | ||
| Q1 24 | -51.0% | -408.8% |
净利率ITPRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | -5.7% | -208.3% | ||
| Q2 25 | -7.9% | -331.8% | ||
| Q1 25 | -32.2% | 6.8% | ||
| Q4 24 | -22.9% | -241.3% | ||
| Q3 24 | -7.9% | -246.3% | ||
| Q2 24 | -0.3% | -237.7% | ||
| Q1 24 | -54.6% | -405.4% |
每股收益（稀释后）ITPRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $-0.11 | $-1.20 | ||
| Q2 25 | $-0.16 | $-1.38 | ||
| Q1 25 | $-0.35 | $0.12 | ||
| Q4 24 | $-0.40 | $-0.99 | ||
| Q3 24 | $-0.20 | $-1.17 | ||
| Q2 24 | $-0.01 | $-1.05 | ||
| Q1 24 | $-0.37 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $4.7M | — |
| 股东权益账面价值 | $152.0M | $102.7M |
| 总资产 | $175.7M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资ITPRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务ITPRGNX
| Q4 25 | — | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $4.7M | — | ||
| Q1 25 | $4.7M | — | ||
| Q4 24 | $4.7M | — | ||
| Q3 24 | $8.9M | — | ||
| Q2 24 | $11.3M | — | ||
| Q1 24 | $11.4M | — |
股东权益ITPRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $152.0M | $161.5M | ||
| Q2 25 | $152.3M | $213.7M | ||
| Q1 25 | $152.8M | $274.2M | ||
| Q4 24 | $156.1M | $259.7M | ||
| Q3 24 | $164.3M | $301.4M | ||
| Q2 24 | $163.5M | $348.3M | ||
| Q1 24 | $164.3M | $390.7M |
总资产ITPRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $175.7M | $525.2M | ||
| Q2 25 | $175.2M | $581.0M | ||
| Q1 25 | $175.2M | $490.9M | ||
| Q4 24 | $177.5M | $466.0M | ||
| Q3 24 | $190.0M | $519.1M | ||
| Q2 24 | $191.4M | $569.4M | ||
| Q1 24 | $177.5M | $629.2M |
负债/权益比ITPRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.03× | — | ||
| Q2 25 | 0.03× | — | ||
| Q1 25 | 0.03× | — | ||
| Q4 24 | 0.03× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $1.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 5.9% | -174.0% |
| 资本支出强度资本支出/营收 | 0.0% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $3.8M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ITPRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $1.5M | $-56.0M | ||
| Q2 25 | $1.4M | $-49.3M | ||
| Q1 25 | $-2.5M | $33.6M | ||
| Q4 24 | $3.5M | $-31.6M | ||
| Q3 24 | $1.5M | $-40.5M | ||
| Q2 24 | $721.9K | $-45.5M | ||
| Q1 24 | $624.4K | $-55.5M |
自由现金流ITPRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $1.5M | $-56.5M | ||
| Q2 25 | $1.3M | $-49.7M | ||
| Q1 25 | $-2.5M | $32.6M | ||
| Q4 24 | $3.5M | $-32.7M | ||
| Q3 24 | $1.2M | $-40.9M | ||
| Q2 24 | $668.3K | $-46.0M | ||
| Q1 24 | $615.4K | $-56.0M |
自由现金流率ITPRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | 5.9% | -189.9% | ||
| Q2 25 | 5.4% | -232.8% | ||
| Q1 25 | -22.8% | 36.6% | ||
| Q4 24 | 19.6% | -154.2% | ||
| Q3 24 | 4.9% | -168.9% | ||
| Q2 24 | 2.5% | -206.2% | ||
| Q1 24 | 9.0% | -358.5% |
资本支出强度ITPRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.1% | 1.8% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 0.1% | 5.1% | ||
| Q3 24 | 1.0% | 1.3% | ||
| Q2 24 | 0.2% | 2.1% | ||
| Q1 24 | 0.1% | 3.6% |
现金转化率ITPRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ITP
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
